Evidence map›Paper›PMID 37679622›Full record

ArticleMethods in molecular biology (Clifton, N.J.)2023

Construction of Semisynthetic Shark vNAR Yeast Surface Display Antibody Libraries.

Harald Kolmar, Julius Grzeschik, Doreen Könning, Simon Krah, Stefan Zielonka

Abstract read
PubMed Publisher
In one paragraph

Article in Methods in molecular biology (Clifton, N.J.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Harald KolmarInstitute for Organic Chemistry and Biochemistry, Technische Universität Darmstadt, Darmstadt, Germany. Kolmar@Biochemie-TUD.de.
Julius GrzeschikInstitute for Organic Chemistry and Biochemistry, Technische Universität Darmstadt, Darmstadt, Germany.
Doreen KönningAntibody-Drug Conjugates and Targeted NBE Therapeutics, Merck KGaA, Darmstadt, Germany.
Simon KrahAntibody Discovery & Protein Engineering, Merck KGaA, Darmstadt, Germany.
Stefan ZielonkaInstitute for Organic Chemistry and Biochemistry, Technische Universität Darmstadt, Darmstadt, Germany. stefan.zielonka@merckgroup.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The adaptive immune system of sharks comprises a unique heavy chain-only antibody isotype, termed immunoglobulin new antigen receptor (IgNAR), in which antigen binding is mediated by a single variable domain, referred to as vNAR. In recent years, efforts were made to harness these domains for biomedical and biotechnological applications particularly due to their high affinity and specificity combined with a small size and high stability. Herein, we describe protocols for the construction of semisynthetic, CDR3-randomized vNAR libraries for the isolation of target-specific paratopes by yeast surface display. Additionally, we provide guidance for affinity maturation of a panel of antigen-enriched vNAR domains through CDR1 diversification of the FACS-selected, antigen-enriched population and sublibrary establishment.

Indexed as

AntibodiesSaccharomyces cerevisiaeAntibodies, FungalImmunoglobulin Heavy ChainsImmunoglobulin IsotypesReceptors, Antigen, B-CellAntibodiesAntibodies, FungalImmunoglobulin Heavy ChainsImmunoglobulin IsotypesReceptors, Antigen, B-CellAffinity maturationAntibody engineeringIgNARLibrary generationProtein engineeringSemisynthetic antibody librarySharkSingle domain antibodyvNARYeast surface display

Identifiers

PMID37679622

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.